A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment

A Phase 1, Multi-center, Open-label, Single-dose Study to Assess the Pharmacokinetics of Mezigdomide (BMS-986348, CC-92480) in Adult Participants With Normal Renal Function, Severe Renal Impairment, and End-stage Renal Disease

The purpose of this study is to evaluate the drug levels of mezigdomide in participants with renal impairment.

Inclusion Criteria

• Participants must have a body mass index (BMI) of ≥ 18.0 kg/m2 to ≤ 40.0 kg/m2 inclusive at screening.
• Participants must have a body weight ≥ 50 kg at screening.
• Participants must be afebrile (febrile is defined as ≥ 38°C or 100.4°F) at screening, check in, and predose.

Exclusion Criteria

• Participants must not have any history of chronic pruritus or dermatologic syndromes that may be confounded with reactions to mezigdomide.
• Participants must not have any history of malignancy of any type other than in situ cervical cancer or surgically excised non-melanomatous skin cancers.
• Participants with an inability to tolerate oral medication.
• Other protocol-defined Inclusion/Exclusion criteria apply.